Brief: Maat Pharma Says MaaT033 Shows Good Safety Profile And Tolerability In ALS Patients
26/11/2024 08:20
Nov 26 (Reuters) - Maat Pharma SA MAAT.PA :
* MAAT PHARMA ANNOUNCES POSITIVE PHASE 1B RESULTS, MEETING
PRIMARY
ENDPOINT IN THE EVALUATION OF MAAT033 IN AMYOTROPHIC LATERAL
SCLEROSIS (ALS)
* MAAT PHARMA SA - MAAT033 SHOWS GOOD SAFETY PROFILE AND
TOLERABILITY IN ALS PATIENTS
Source text: ID:nBw6fhj39a
Further company coverage: MAAT.PA
(((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on Maat Pharma SA
See all newsBrief: MaaT Pharma Says FDA Indicates No Additional Nonclinical Studies Required For MaaT034 Safety
France's MaaT Pharma H1 operating loss widens on higher R&D costs
Brief: MaaT Pharma SA Receives 'Negative Trend' Opinion For Upcoming June CHMP Vote For MaaT013 (Xervyteg)
France's MaaT Pharma 2025 revenue rises 40.7% but misses expectations
Brief: MaaT Pharma Says Xervyteg Under EMA Review, Decision Expected In H2 2026